Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK.

BJU Int. 2013 Mar;111(3):437-50. doi: 10.1111/j.1464-410X.2012.11597.x. Epub 2012 Dec 28.

2.

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH.

Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26.

3.

Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia.

Sais G, Wyler S, Hudolin T, Banzola I, Mengus C, Bubendorf L, Wild PJ, Hirsch HH, Sulser T, Spagnoli GC, Provenzano M.

J Virol. 2012 Aug;86(16):8461-71. doi: 10.1128/JVI.00005-12. Epub 2012 May 30.

4.

Survivin is a potential mediator of prostate cancer metastasis.

Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, Chakravarti A.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1095-103. doi: 10.1016/j.ijrobp.2009.09.007. Epub 2010 Mar 16.

Supplemental Content

Support Center